Akorn Inc (AKRX) 36.37 $AKRX
Acquisition-Hungry Akorn Sets Up Potential Buy Area
at Investor's Business Daily - Mon Sep 22, 5:10PM CDT
Even if you miss a leading stock at its breakout, don't feel compelled to chase it. It could set up a second, or in some cases even a third, opportunity to get in. Akorn (AKRX) broke out past a 25.19 cup-with-handle buy point in late April and ran up...
Akorn Has Returned 47.9% Since SmarTrend Recommendation (AKRX)
Comtex SmarTrend(R) - Mon Sep 22, 10:59AM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 5 months, Akorn has returned 47.90% as of today's recent price of $36.31.
IBD 50 Stocks Setting Up, Including These 5 Medicals
at Investor's Business Daily - Fri Sep 19, 6:36PM CDT
Recent volatility in the stock market, including an outlook shift to uptrend under pressure and back to a confirmed uptrend, may have rattled investors' nerves. But it's also helped set up new potential entries as some leading stocks slipped into buy...
IBD 50: Akorn Aims For $1 Billion In Sales
at Investor's Business Daily - Fri Sep 19, 5:35PM CDT
Drugmaker Akorn has set its sights on becoming a company with $1 billion in annual sales. One way that it's trying to reach that goal is by making acquisitions. Lake Forest, Ill.-based Akorn (AKRX) is still a ways from its goal, with $318 million in...
Impax Rytary FDA Action Date Extended by Three Months - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:30PM CDT
The FDA has pushed back the PDUFA date for Impax Laboratories, Inc.'s Rytary by three months to Jan 9, 2015.
Will Drugmaker Akorn Have A Healthy Bounce Up?
at Investor's Business Daily - Thu Sep 18, 11:09AM CDT
Today let's check out Akorn (AKRX), a pharmaceutical company based in Illionois. The firm develops specialty drugs for use in ophthalmology, hospitals and as injectables. Last month the drugmaker reported second-quarter earnings that beat estimates...
Stocks with Upgraded Broker Ratings - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Sep 16, 2:57AM CDT
Stocks with Upgraded Broker Ratings - Screen of the Week
Akorn Shares Up 50.4% Since SmarTrend's Buy Recommendation (AKRX)
Comtex SmarTrend(R) - Mon Sep 15, 9:39AM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 5 months, Akorn has returned 50.41% as of today's recent price of $36.92.
Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers
at Investor's Business Daily - Sat Sep 13, 7:02AM CDT
Biotech and pharmaceutical companies are on the rise with life-saving promises, adding to hopes that their stocks will also be healthy investments. The industry was down Friday on general market weakness and concerns over growth stocks. But it...
Akorn said eyeing tax inversion
at Investor's Business Daily - Fri Sep 12, 6:01PM CDT
The specialty-drug maker is exploring a $2 bil bid for Belgian drugmaker UCB's U.S. subsidiary in that country, a deal that would let it move its headquarters overseas to save on taxes, Reuters said, citing sources. UCB was earlier reported to be...
AbbVie's Humira Positive in Phase III Skin Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:05PM CDT
AbbVie Inc.'s (ABBV) Humira met the primary endpoint in a late-stage study conducted in patients suffering from moderate-to-severe hidradenitis suppurativa.
5 Top Stocks With Rising Earnings Estimates
at Investor's Business Daily - Fri Sep 12, 7:02AM CDT
It might be far from earnings season, but it's still a good time to look at companies with strong earnings potential -- like BitAuto (BITA), which is cruising in the fast lane of China's middle-class auto-buying spree. The China-based company runs a...
Akorn In Second Test Of 10-Week Line
at Investor's Business Daily - Thu Sep 11, 5:19PM CDT
Akorn has pulled back to its 10-week moving average, thus setting up a buying opportunity. Rebounds are tricky as there's no specific buy point. But the idea is to buy as close to the 10-week line as possible, especially if there's big volume. Volume...
SmarTrend Watching for Potential Pullback in Shares of Akorn After 3.36% Gain
Comtex SmarTrend(R) - Thu Sep 11, 4:34PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $35.63 to a high of $38.27. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $38.10 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks Show Modest Losses; Biotechs Pressured Again
at Investor's Business Daily - Thu Sep 11, 1:46PM CDT
Major averages showed modest losses with a little over one hour remaining in Thursday's session. The Nasdaq lost 0.2%, hurt somewhat by a fresh round of selling in biotechland. The Dow Jones industrial average and S&P 500 gave up 0.2% and 0.1%,...
Actavis' Bystolic Combination Gets Negative FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:45PM CDT
Actavis plc (ACT) announced that the FDA's CRDAC has voted against the approval (in the ratio of 6:4) of Actavis' fixed-dose combination (FDC) of Bystolic (nebivolol) and Novartis' (NVS) Diovan (valsartan).
Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:20PM CDT
Actavis plc (ACT) announced the acceptance of its new drug application for its antibiotic candidate, ceftazidime-avibactam, by the FDA.
Akorn Has Returned 53.7% Since SmarTrend Recommendation (AKRX)
Comtex SmarTrend(R) - Mon Sep 08, 9:07AM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 5 months, Akorn has returned 53.73% as of today's recent price of $37.74.
Technical Snapshot on Pharma Stocks - Allergan, Akorn, Mallinckrodt, Mylan, and AVANIR Pharma
PR Newswire - Mon Sep 08, 8:25AM CDT
On Friday, September 5, 2014, the NASDAQ Composite ended at 4,582.90, up 0.45%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,137.36, and the S&P 500 closed at 2,007.71, up 0.50%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.23, up 0.57%, with the index also advancing 6.70% in the last three months. Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Akorn Inc. (NASDAQ: AKRX), Mallinckrodt PLC (NYSE: MNK), Mylan Inc. (NASDAQ: MYL), and AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR). Free research on these five companies can be accessed at:
Acquisition-Hungry Akorn Sets Up Potential Buy Area
at Investor's Business Daily - Mon Sep 22, 5:10PM CDT
Even if you miss a leading stock at its breakout, don't feel compelled to chase it. It could set up a second, or in some cases even a third, opportunity to get in. Akorn (AKRX) broke out past a 25.19 cup-with-handle buy point in late April and ran up...
Akorn Has Returned 47.9% Since SmarTrend Recommendation (AKRX)
Comtex SmarTrend(R) - Mon Sep 22, 10:59AM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 5 months, Akorn has returned 47.90% as of today's recent price of $36.31.
IBD 50 Stocks Setting Up, Including These 5 Medicals
at Investor's Business Daily - Fri Sep 19, 6:36PM CDT
Recent volatility in the stock market, including an outlook shift to uptrend under pressure and back to a confirmed uptrend, may have rattled investors' nerves. But it's also helped set up new potential entries as some leading stocks slipped into buy...
IBD 50: Akorn Aims For $1 Billion In Sales
at Investor's Business Daily - Fri Sep 19, 5:35PM CDT
Drugmaker Akorn has set its sights on becoming a company with $1 billion in annual sales. One way that it's trying to reach that goal is by making acquisitions. Lake Forest, Ill.-based Akorn (AKRX) is still a ways from its goal, with $318 million in...
Impax Rytary FDA Action Date Extended by Three Months - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:30PM CDT
The FDA has pushed back the PDUFA date for Impax Laboratories, Inc.'s Rytary by three months to Jan 9, 2015.
Will Drugmaker Akorn Have A Healthy Bounce Up?
at Investor's Business Daily - Thu Sep 18, 11:09AM CDT
Today let's check out Akorn (AKRX), a pharmaceutical company based in Illionois. The firm develops specialty drugs for use in ophthalmology, hospitals and as injectables. Last month the drugmaker reported second-quarter earnings that beat estimates...
Stocks with Upgraded Broker Ratings - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Sep 16, 2:57AM CDT
Stocks with Upgraded Broker Ratings - Screen of the Week
Akorn Shares Up 50.4% Since SmarTrend's Buy Recommendation (AKRX)
Comtex SmarTrend(R) - Mon Sep 15, 9:39AM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 5 months, Akorn has returned 50.41% as of today's recent price of $36.92.
Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers
at Investor's Business Daily - Sat Sep 13, 7:02AM CDT
Biotech and pharmaceutical companies are on the rise with life-saving promises, adding to hopes that their stocks will also be healthy investments. The industry was down Friday on general market weakness and concerns over growth stocks. But it...
Akorn said eyeing tax inversion
at Investor's Business Daily - Fri Sep 12, 6:01PM CDT
The specialty-drug maker is exploring a $2 bil bid for Belgian drugmaker UCB's U.S. subsidiary in that country, a deal that would let it move its headquarters overseas to save on taxes, Reuters said, citing sources. UCB was earlier reported to be...
AbbVie's Humira Positive in Phase III Skin Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:05PM CDT
AbbVie Inc.'s (ABBV) Humira met the primary endpoint in a late-stage study conducted in patients suffering from moderate-to-severe hidradenitis suppurativa.
5 Top Stocks With Rising Earnings Estimates
at Investor's Business Daily - Fri Sep 12, 7:02AM CDT
It might be far from earnings season, but it's still a good time to look at companies with strong earnings potential -- like BitAuto (BITA), which is cruising in the fast lane of China's middle-class auto-buying spree. The China-based company runs a...
Akorn In Second Test Of 10-Week Line
at Investor's Business Daily - Thu Sep 11, 5:19PM CDT
Akorn has pulled back to its 10-week moving average, thus setting up a buying opportunity. Rebounds are tricky as there's no specific buy point. But the idea is to buy as close to the 10-week line as possible, especially if there's big volume. Volume...
SmarTrend Watching for Potential Pullback in Shares of Akorn After 3.36% Gain
Comtex SmarTrend(R) - Thu Sep 11, 4:34PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $35.63 to a high of $38.27. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $38.10 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks Show Modest Losses; Biotechs Pressured Again
at Investor's Business Daily - Thu Sep 11, 1:46PM CDT
Major averages showed modest losses with a little over one hour remaining in Thursday's session. The Nasdaq lost 0.2%, hurt somewhat by a fresh round of selling in biotechland. The Dow Jones industrial average and S&P 500 gave up 0.2% and 0.1%,...
Actavis' Bystolic Combination Gets Negative FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:45PM CDT
Actavis plc (ACT) announced that the FDA's CRDAC has voted against the approval (in the ratio of 6:4) of Actavis' fixed-dose combination (FDC) of Bystolic (nebivolol) and Novartis' (NVS) Diovan (valsartan).
Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:20PM CDT
Actavis plc (ACT) announced the acceptance of its new drug application for its antibiotic candidate, ceftazidime-avibactam, by the FDA.
Akorn Has Returned 53.7% Since SmarTrend Recommendation (AKRX)
Comtex SmarTrend(R) - Mon Sep 08, 9:07AM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 5 months, Akorn has returned 53.73% as of today's recent price of $37.74.
Technical Snapshot on Pharma Stocks - Allergan, Akorn, Mallinckrodt, Mylan, and AVANIR Pharma
PR Newswire - Mon Sep 08, 8:25AM CDT
On Friday, September 5, 2014, the NASDAQ Composite ended at 4,582.90, up 0.45%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,137.36, and the S&P 500 closed at 2,007.71, up 0.50%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.23, up 0.57%, with the index also advancing 6.70% in the last three months. Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Akorn Inc. (NASDAQ: AKRX), Mallinckrodt PLC (NYSE: MNK), Mylan Inc. (NASDAQ: MYL), and AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR). Free research on these five companies can be accessed at:
